Suppression of peripheral pain by blockade of voltage-gated calcium 2.2 channels in nociceptors induces RANKL and impairs recovery from inflammatory arthritis in a mouse model

Arthritis and Rheumatology

Volumn 67, Issue 6, 2015, Pages 1657-1667

  Baddack, Uta ^a,b   Frahm, Silke ^c   Antolin Fontes, Beatriz ^d   Grobe, Jenny ^a   Lipp, Martin ^a   Müller, Gerd ^a   Ibañez Tallon, Ines ^d  

^a MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^b CNRS   (France)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; OMEGA CONOTOXIN MVIIA; OSTEOCLAST DIFFERENTIATION FACTOR; UNCLASSIFIED DRUG; VOLTAGE GATED CALCIUM 2.2 CHANNEL; VOLTAGE GATED CALCIUM CHANNEL; CACNA1B PROTEIN, MOUSE; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL N TYPE; OMEGA CONOTOXIN; TNFSF11 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTHRITIS; ARTICLE; AUTOIMMUNITY; CALCIUM TRANSPORT; CHRONIC PAIN; CONTROLLED STUDY; CYTOKINE RELEASE; IMMUNOLOGICAL TOLERANCE; KNEE; MOTOR ACTIVITY; MOUSE; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; OSTEOCLASTOGENESIS; PAIN RECEPTOR; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SENSORY NERVE CELL; SYNAPTOSOME; UPREGULATION; ANIMAL; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; DISEASE MODEL; GENETICS; HINDLIMB; IMMUNOLOGY; METABOLISM; NOCICEPTIVE PAIN; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, N-TYPE; DISEASE MODELS, ANIMAL; MICE; MICE, TRANSGENIC; NOCICEPTIVE PAIN; NOCICEPTORS; OMEGA-CONOTOXINS; RANK LIGAND; STIFLE; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84929887430     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39094     Document Type: Article

References (43)

1. Firestein GS,. Evolving concepts of rheumatoid arthritis. Nature 2003; 423: 356-61.
2. Kosek E, Ordeberg G,. Abnormalities of somatosensory perception in patients with painful osteoarthritis normalize following successful treatment. Eur J Pain 2000; 4: 229-38.
3. Kindler LL, Bennett RM, Jones KD., Central sensitivity syndromes: mounting pathophysiologic evidence to link fibromyalgia with other common chronic pain disorders. Pain Manag Nurs 2011; 12: 15-24.
4. Lee YC, Nassikas NJ, Clauw DJ., The role of the central nervous system in the generation and maintenance of chronic pain in rheumatoid arthritis, osteoarthritis and fibromyalgia. Arthritis Res Ther 2011; 13: 211.
5. Snider WD, McMahon SB., Tackling pain at the source: new ideas about nociceptors. Neuron 1998; 20: 629-32.
6. Dray A, Read S., Arthritis and pain: future targets to control osteoarthritis pain. Arthritis Res Ther 2007; 9: 212.
7. Wang YX, Gao D, Pettus M, Phillips C, Bowersox SS., Interactions of intrathecally administered ziconotide, a selective blocker of neuronal N-type voltage-sensitive calcium channels, with morphine on nociception in rats. Pain 2000; 84: 271-81.
8. Carstens BB, Clark RJ, Daly NL, Harvey PJ, Kaas Q, Craik DJ., Engineering of conotoxins for the treatment of pain. Curr Pharm Des 2011; 17: 4242-53.
9. Auer S, Sturzebecher AS, Juttner R, Santos-Torres J, Hanack C, Frahm S, et al., Silencing neurotransmission with membrane-tethered toxins. Nat Methods 2010; 7: 229-36.
10. Schellekens GA, Visser H, de Jong BA, van den Hoogen FH, Hazes JM, Breedveld FC, et al., The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000; 43: 155-63.
11. Harre U, Georgess D, Bang H, Bozec A, Axmann R, Ossipova E, et al., Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 2012; 122: 1791-802.
12. Baddack U, Hartmann S, Bang H, Grobe J, Loddenkemper C, Lipp M, et al., A chronic model of arthritis supported by a strain-specific periarticular lymph node in BALB/c mice. Nat Commun 2013; 4: 1644.
13. Feldmann M, Maini RN., Discovery of TNF-α as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies. Joint Bone Spine 2002; 69: 12-8.
14. Schett G., Immune cells and mediators of inflammatory arthritis [review]. Autoimmunity 2008; 41: 224-9.
15. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al., Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402: 304-9.
16. Shigeyama Y, Pap T, Kunzler P, Simmen BR, Gay RE, Gay S., Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum 2000; 43: 2523-30.
17. Pettit AR, Walsh NC, Manning C, Goldring SR, Gravallese EM., RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 1068-76.
18. Just S, Leipold-Buttner C, Heppelmann B., Histological demonstration of voltage dependent calcium channels on calcitonin gene-related peptide-immunoreactive nerve fibres in the mouse knee joint. Neurosci Lett 2001; 312: 133-6.
19. Wichner K, Fischer A, Winter S, Tetzlaff S, Heimesaat MM, Bereswill S, et al., Transition from an autoimmune-prone state to fatal autoimmune disease in CCR7 and RORγt double-deficient mice is dependent on gut microbiota. J Autoimmun 2013; 47: 58-72.
20. Schaible HG, Ebersberger A, Von Banchet GS., Mechanisms of pain in arthritis. Ann N Y Acad Sci 2002; 966: 343-54.
21. Chiu IM, von Hehn CA, Woolf CJ., Neurogenic inflammation and the peripheral nervous system in host defense and immunopathology. Nat Neurosci 2012; 15: 1063-7.
22. Caceres AI, Brackmann M, Elia MD, Bessac BF, del Camino D, D'Amours M, et al., A sensory neuronal ion channel essential for airway inflammation and hyperreactivity in asthma. Proc Natl Acad Sci U S A 2009; 106: 9099-104.
23. Engel MA, Leffler A, Niedermirtl F, Babes A, Zimmermann K, Filipovic MR, et al., TRPA1 and substance P mediate colitis in mice. Gastroenterology 2011; 141: 1346-58.
24. Levine JD, Clark R, Devor M, Helms C, Moskowitz MA, Basbaum AI., Intraneuronal substance P contributes to the severity of experimental arthritis. Science 1984; 226: 547-9.
25. Ostrowski SM, Belkadi A, Loyd CM, Diaconu D, Ward NL., Cutaneous denervation of psoriasiform mouse skin improves acanthosis and inflammation in a sensory neuropeptide-dependent manner. J Invest Dermatol 2011; 131: 1530-8.
26. Sluka KA, Rasmussen LA, Edgar MM, O'Donnell JM, Walder RY, Kolker SJ, et al., Acid-sensing ion channel 3 deficiency increases inflammation but decreases pain behavior in murine arthritis. Arthritis Rheum 2013; 65: 1194-202.
27. Lewin GR, Lechner SG, Smith ES., Nerve growth factor and nociception: from experimental embryology to new analgesic therapy. Handb Exp Pharmacol 2014; 220: 251-82.
28. Seidel MF, Lane NE., Control of arthritis pain with anti-nerve-growth factor: risk and benefit. Curr Rheumatol Rep 2012; 14: 583-8.
29. European Medicines Agency. European Public Assessment Report (EPAR) for authorized medicinal products for human use; scientific discussion. 2005. URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Scientific-Discussion/human/000551/WC500041926.pdf.
30. Winquist RJ, Pan JQ, Gribkoff VK., Use-dependent blockade of Cav2.2 voltage-gated calcium channels for neuropathic pain. Biochem Pharmacol 2005; 70: 489-99.
31. 2+ channel complex. Nat Med 2011; 17: 822-9.
32. Stolina M, Adamu S, Ominsky M, Dwyer D, Asuncion F, Geng Z, et al., RANKL is a marker and mediator of local and systemic bone loss in two rat models of inflammatory arthritis. J Bone Miner Res 2005; 20: 1756-65.
33. Lloyd S, Bujkiewicz S, Wailoo AJ, Sutton AJ, Scott D., The effectiveness of anti-TNF-α therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis. Rheumatology (Oxford) 2010; 49: 2313-21.
34. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al., Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-76.
35. Lewiecki EM., New targets for intervention in the treatment of postmenopausal osteoporosis. Nat Rev Rheumatol 2011; 7: 631-8.
36. Tokuhara N, Namiki K, Uesugi M, Miyamoto C, Ohgoh M, Ido K, et al., N-type calcium channel in the pathogenesis of experimental autoimmune encephalomyelitis. J Biol Chem 2010; 285: 33294-306.
37. Li W, Wang T, Ma C, Xiong T, Zhu Y, Wang X,. Calcitonin gene-related peptide inhibits interleukin-1β-induced endogenous monocyte chemoattractant protein-1 secretion in type II alveolar epithelial cells. Am J Physiol Cell Physiol 2006; 291: C456-65.
38. Kilo S, Harding-Rose C, Hargreaves KM, Flores CM., Peripheral CGRP release as a marker for neurogenic inflammation: a model system for the study of neuropeptide secretion in rat paw skin. Pain 1997; 73: 201-7.
39. Garrett NE, Kidd BL, Cruwys SC, Tomlinson DR., Changes in preprotachykinin mRNA expression and substance P levels in dorsal root ganglia of monoarthritic rats: comparison with changes in synovial substance P levels. Brain Res 1995; 675: 203-7.
40. Konttinen YT, Hukkanen M, Segerberg M, Rees R, Kemppinen P, Sorsa T, et al., Relationship between neuropeptide immunoreactive nerves and inflammatory cells in adjuvant arthritic rats. Scand J Rheumatol 1992; 21: 55-9.
41. Keeble JE, Brain SD., A role for substance P in arthritis? Neurosci Lett 2004; 361: 176-9.
42. Mantyh PW, Yaksh TL., Sensory neurons are PARtial to pain. Nat Med 2001; 7: 772-3.
43. Just S, Heppelmann B., Voltage-gated calcium channels may be involved in the regulation of the mechanosensitivity of slowly conducting knee joint afferents in rat. Exp Brain Res 2003; 150: 379-84.